Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM-ALL 2009

Next Previous
Trial Profile

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM-ALL 2009

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crisantaspase (Primary) ; Pegaspargase (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Daunorubicin liposomal; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Ifosfamide; Mercaptopurine; Mesna; Methotrexate; Methotrexate; Methotrexate; Prednisolone; Prednisone; Tioguanine; Vincristine; Vindesine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms AIEOP-BFM-ALL2009

Most Recent Events

  • 10 Dec 2024 Results assessing the outcomes of children with T-cell acute lymphoblastic leukemia (T-ALL) treated on the this study and to identify and refine prognostic factors for risk stratification were published at the 66th American Society of Hematology Annual Meeting and Exposition.
  • 10 Dec 2024 Results showing a 50% reduction of the cumulative DNR dose during induction not compromising the outcome, presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 13 Dec 2022 Results (n=6136; From June 1, 2010 to February 28, 2017) assessing an intensive and continuous exposure to pegylated L-Asparaginase (Peg-L-ASP), given on top of BFM consolidation phase IB, could decrease the levels of MRD and to influence long term outcome, presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top